Pricing and Reimbursement in Oncology
|腫瘤學的價格與償付 Pricing and Reimbursement in Oncology|
|出版日期: 2020年03月05日||內容資訊: 英文||
Specialised cancer therapies such as checkpoint inhibitors have significantly improved outcomes for patients but for payers they represent a growing funding challenge, especially as triple and quadruple oncology therapy becomes common place. To achieve the widest possible access to patients, pharma needs payers positively on board, so what must developers do to get payer support for their oncology product pricing and reimbursement ambitions? Understanding the pressures and touchpoints that resonate with payers is critical. In this report, US and European payers reveal their attitudes and needs and the practical steps pharma can take to address their concerns.